Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  ChemoCentryx, Inc.    CCXI

CHEMOCENTRYX, INC.

(CCXI)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/24/2020 02/25/2020 02/26/2020 02/27/2020 02/28/2020 Date
47(c) 46.37(c) 46.05(c) 44.18(c) 44.75 Last
514 887 749 999 459 982 555 453 1 023 799 Volume
-3.83% -1.34% -0.69% -4.06% +1.29% Change
More quotes
Financials (USD)
Sales 2019 35,7 M
EBIT 2019 -58,2 M
Net income 2019 -55,5 M
Finance 2019 150 M
Yield 2019 -
Sales 2020 33,3 M
EBIT 2020 -93,7 M
Net income 2020 -92,1 M
Finance 2020 81,7 M
Yield 2020 -
P/E ratio 2019 -45,7x
P/E ratio 2020 -29,6x
EV / Sales2019 68,9x
EV / Sales2020 75,9x
Capitalization 2 608 M
More Financials
Company
ChemoCentryx, Inc. is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or... 
Sector
Pharmaceuticals
Calendar
03/12Earnings Release
More about the company
Surperformance© ratings of ChemoCentryx, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on CHEMOCENTRYX, INC.
02/19ChemoCentryx to Present at the 9th Annual SVB Leerink Global Healthcare Confe..
GL
01/16CHEMOCENTRYX, INC. : Regulation FD Disclosure, Financial Statements and Exhibits..
AQ
01/10CHEMOCENTRYX, INC. : Entry into a Material Definitive Agreement, Creation of a D..
AQ
01/09ChemoCentryx Announces Credit Facility of Up to $100 Million with Hercules Ca..
GL
01/08ChemoCentryx to Present at the 38th Annual JP Morgan Healthcare Conference
GL
2019CHEMOCENTRYX : Vifor Pharma - VFMCRP and ChemoCentryx announce positive topline ..
AQ
2019CHEMOCENTRYX : and VFMCRP Announce Positive Topline Data from Pivotal Phase III ..
AQ
2019ChemoCentryx to Present at the 31st Annual Piper Jaffray Healthcare Conferenc..
GL
2019CHEMOCENTRYX : VFMCRP and ChemoCentryx Announce Positive Topline Data From Pivot..
BU
2019CHEMOCENTRYX, INC. : Regulation FD Disclosure, Other Events, Financial Statement..
AQ
2019ChemoCentryx and VFMCRP Announce Positive Topline Data from Pivotal Phase III..
GL
2019CHEMOCENTRYX : Presentations at ASN Kidney Week 2019 Highlight Breadth of ChemoC..
AQ
2019Presentations at ASN Kidney Week 2019 Highlight Breadth of ChemoCentryx Platf..
GL
2019CHEMOCENTRYX : 3Q Earnings Snapshot
AQ
2019CHEMOCENTRYX : Management's Discussion and Analysis of Financial Condition and R..
AQ
More news
News in other languages on CHEMOCENTRYX, INC.
2018CHEMOCENTRYX INC : Veröffentlichung des Jahresergebnisses
2018CHEMOCENTRYX INC : publication des résultats annuels
2016CHEMOCENTRYX INC : Veröffentlichung des Jahresergebnisses
2014Wall Street ouvre dans le rouge, des statistiques pèsent
More news
Analyst Recommendations on CHEMOCENTRYX, INC.
More recommendations
Chart CHEMOCENTRYX, INC.
Duration : Period :
ChemoCentryx, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHEMOCENTRYX, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Average target price 57,33  $
Last Close Price 44,55  $
Spread / Highest target 43,7%
Spread / Average Target 28,7%
Spread / Lowest Target 12,2%
EPS Revisions
Managers
NameTitle
Thomas J. Schall Chairman, President & Chief Executive Officer
Susan M. Kanaya Chief Financial & Administrative Officer, SVP
Geoffrey M. Parker Independent Director
Joseph M. Feczko Independent Director
James L. Tyree Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CHEMOCENTRYX, INC.11.71%2 574
CSL LIMITED15.14%94 808
BIOGEN INC.4.50%53 974
SAMSUNG BIOLOGICS CO.,LTD.0.21%26 246
GRIFOLS-1.11%20 625
ALEXION PHARMACEUTICALS-12.36%20 389